Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.55 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16046274 | 0.89 | FAAH (0.53) | FAAHALDH1A1LMNAHSD17B10NPSR1 | |
| Glycerin SCHEMBL27923640 | 0.85 | FAAH (0.45) | CES2CES1FAAHALDH1A1FFAR3 | |
| SCHEMBL3840637 | 0.85 | CES2 (0.50) | CES2CES1FAAHALDH1A1FFAR3 | |
| SCHEMBL910019 | 0.85 | FAAH (0.67) | CES2CES1FAAHALDH1A1LMNA | |
| SCHEMBL3020461 | 0.84 | GAA (0.44) | CES2CES1FAAHALDH1A1FFAR3 | |
| SCHEMBL18101453 | 0.84 | FAAH (0.60) | CES2CES1FAAHALDH1A1LMNA | |
| SCHEMBL3014656 | 0.83 | FAAH (0.76) | CES2CES1FAAHALDH1A1HSD17B10 | |
| SCHEMBL909822 | 0.82 | CES2 (0.52) | CES2CES1FAAHALDH1A1FFAR3 | |
| SCHEMBL28233813 | 0.82 | FAAH (0.48) | FAAHALDH1A1LMNAHSD17B10NPSR1 | |
| SCHEMBL10704882 | 0.82 | FAAH (0.69) | CES2CES1FAAHALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004771-A | Method for producing organic sulfinate compound | 中国石油化工股份有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-112047998-B | Preparation method of perindopril | 上海阿达玛斯试剂有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-113527867-B | High-resilience antibacterial TPU (thermoplastic polyurethane) foam material and preparation method thereof | 福建师范大学泉港石化研究院 | 2022-06-14 | — | — | CN | claimed |
| CN-111440492-B | Coating with slow-release fragrance | 广东佰朋实业有限公司 | 2021-12-10 | — | — | CN | claimed |
| CN-113527867-A | High-resilience antibacterial TPU (thermoplastic polyurethane) foam material and preparation method thereof | 福建师范大学泉港石化研究院 | 2021-10-22 | — | — | CN | claimed |
| CN-112047998-A | Preparation method of perindopril | 上海阿达玛斯试剂有限公司 | 2020-12-08 | — | — | CN | claimed |
| CN-111499657-A | Synthetic method of isoquinoline oxazolidine | 蚌埠学院 | 2020-08-07 | — | — | CN | claimed |
| CN-111440492-A | Coating with slow-release fragrance | 张孟杰 | 2020-07-24 | — | — | CN | claimed |
| WO-2020002138-A1 | C5 OR C6 ACID ESTER-BASED CATALYST AND USE THEREOF IN A HYDROPROCESSING AND/OR HYDROCRACKING PROCESS | IFP Energies Nouvelles (FR) | 2020-01-02 | — | — | WO | claimed |
| US-20170239154-A1 | PYRUVATE AND RELATED ALPHA-KETO CARBOXYLATES AS NOVEL ADJUVANTS IN THE TREATMENT OF POST TOOTH WHITENING SENSITIVITY AND THE TISSUE PROTECTIVE EFFECT OF PYRUVATE ON THE ORAL SOFT TISSUE | RUSZNAK ZOLTAN (US) | 2017-08-24 | — | — | US | claimed |
| EP-1494659-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | Critical Therapeutics, Inc. (US) | 2005-01-12 | — | — | EP | claimed |
| US-20040110833-A1 | Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2004-06-10 | — | — | US | claimed |
| EP-1379230-A1 | METHOD OF USING PYRUVATE AND/OR ITS DERIVATIVES FOR THE TREATMENT OF CYTOKINE-MEDIATED INFLAMMATORY CONDITIONS | University of Pittsburgh of the Commonwealth System of Higher Education (US) | 2004-01-14 | — | — | EP | claimed |
| US-20030232884-A1 | New pharmaceutical formulation | CRITICAL THERAPEUTICS, INC. | 2003-12-18 | — | — | US | claimed |
| US-20030216470-A1 | Method for treating ileus | CRITICAL THERAPEUTICS, INC. | 2003-11-20 | — | — | US | claimed |
| WO-2003088955-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMINE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-20030073743-A1 | Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion | XANTHUS LIFE SCIENCES, INC. (CA) | 2003-04-17 | — | — | US | claimed |
| WO-2002074301-A1 | METHOD OF USING PYRUVATE AND/OR ITS DERIVATIVES FOR THE TREATMENT OF CYTOKINE-MEDIATED INFLAMMATORY CONDITIONS | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-26 | — | — | WO | claimed |
| EP-1233767-A1 | PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION | Xanthus Life Sciences, Inc. (CA) | 2002-08-28 | — | — | EP | claimed |
| WO-2001024793-A1 | PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION | XANTHUS LIFE SCIENCES, INC. (CA) | 2001-04-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232884-A1 | New pharmaceutical formulation | LIPA, CEL, LDHA | CES2 2709/4885CES1 890/4885FAAH 88/4885 |
| US-20040110833-A1 | Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions | HMGB1, HMGB2, HMGB3 | CES2 4394/4885CES1 622/4885FAAH 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.